article thumbnail

Vault Snack #30 – Additional Curve Fits for Plotting and Analysing Assay Data in CDD Vault

Collaborative Drug

Skip to content Login Search { Products CDD Vault Why CDD Vault Core Functionality Registration Activity Visualization Assays Add-ons ELN Inventory Curves AI AI + Automation Solutions Applications Assay Data Management Macrocycle Protein Therapeutic CRISPR PROTAC Antibody Drug Conjugate Small Molecules & Mixtures Industries Biotech & Pharmaceutical (..)

article thumbnail

October CMS: A Modern CMS for Developers and Creators

Perficient: Drug Development

testimonials or client inquiries). The CMS allows easy updates to content and media without relying on a developer. Supports galleries, animations, and custom templates to help creatives stand out. Extendable with contact forms and user interactions (e.g., eCommerce Sites Ideal For: Online stores of any size.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Growing Trend of Patient-Led Clinical Research in Rare Disease

Conversations in Drug Development Trends

These meetings are designed for attendees to hear testimonies from clinicians, patients, caregivers, and families about the issues facing these stakeholder groups in the diagnosis, treatment, and long-term prognosis of a disease as it is experienced in real life – not through an impersonal, peer-reviewed case report.

article thumbnail

Schedule III Marijuana Would Still Be Regulated Marijuana

FDA Law Blog: Biosimilars

In January a public hearing began to receive factual evidence and testimony on whether marijuana should be rescheduled. DEA published a Notice of Proposed Rulemaking (NPRM), signed by Attorney General Merrick Garland, proposing to reschedule marijuana in May 2024 that elicited over 43,500 comments.

article thumbnail

DEA Pharmacy Decision Highlights Agency’s Thinking on Expert Credibility and Testimony, as well as Red Flag Resolution

FDA Law Blog: Biosimilars

Hull A recent DEA decision revoking the registration of a Louisiana pharmacy sheds light on the Agencys approach to crediting one experts testimony over that of another expert during an administrative hearing. The hearing involved dueling expert testimony on the pharmacy standard of care in Louisiana from both DEA and the respondent.

article thumbnail

Salt Lake City

Alta Sciences

All Rights Reserved. Cookie Policy | Privacy Policy Have a question? × Id be happy to help.

article thumbnail

Gretchen Green

Alta Sciences

All Rights Reserved. Cookie Policy | Privacy Policy Have a question? × Id be happy to help.